RESUMO
Objective To evaluate the safety and efficiency of the unibody bifurcate endografts in treating aortoiliac occlusive disease. Methods We performed a retrospective review of patients with aortoiliac occlusive disease who underwent endovascular revascularization with unibody bifurcated endografts. Data of demography, operative details, and outcomes were collected. Results From March 2016 to December 2017, 7 patients (6 males and 1 female) were treated using this endovascular technique. Technical success was achieved in all patients and there were no procedure related complications. The aortoiliac reconstructions remained patent within the median follow up of 11.0 (range 6.3-21.3) months, and all the patients clinically were improved an average of 1.71 Rutherford categories. Conclusions Endovascular repairment using an unibody bifurcated endograft for aortoiliac occlusive disease is feasible and effective, and has excellent short and midterm patency; however, the long?term patency need to be consequently observed.
